Optimized expression of HPV 52 L1 in yeast

Details Optimized expression of HPV 52 L1 in yeast Optimized expression of HPV 52 L1 in yeast

2009-10-14

2010-06-29

Rao, Manjunath N (Department: 1656)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C435S320100, C435S255100, C435S069100

Reexamination Certificate

active

07744892

ABSTRACT:
Synthetic DNA molecules encoding the HPV 52 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV 52 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. In alternative embodiments of the invention, the nucleotide sequence of the synthetic molecule is altered to eliminate transcription termination signals that are recognized by yeast. The synthetic molecules may be used to produce HPV 52 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV 52 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and may also be useful for treatment of existing HPV infections.

REFERENCES:
patent: 5643715 (1997-07-01), Lancaster
patent: 5821087 (1998-10-01), Lowe et al.
patent: 6159729 (2000-12-01), Hofmann et al.
patent: 7276243 (2007-10-01), Jansen et al.
patent: 98/34640 (1998-08-01), None
patent: 99/02694 (1999-01-01), None
patent: 00/09157 (2000-02-01), None
patent: 01/14416 (2001-03-01), None
patent: 01/28585 (2001-04-01), None
patent: 02/08435 (2002-01-01), None
patent: 2004/084831 (2004-10-01), None
patent: 2005/032586 (2005-04-01), None
patent: 2005/047315 (2005-05-01), None
Bosch et al., “The casual relation between human papillomavirus and cervical cancer”, Journal of Clinical Pathology, 2002, vol. 55, pp. 244-265.
Breitburd et al., “Immunization with Viruslike Particles from Cottontail Rabbit Papillomavirus (CRPV) Can Protect against Experimental CRPV Infection”, Journal of Virology, 1995, vol. 69, pp. 3959-3963.
Chan et al., “Phylogenetic Analysis of 48 Papillomavirus Types and 28 Subtypes and Variants: a Showcase for the Molecular Evolution of DNA Viruses”, Journal of Virology, 1992, vol. 66, pp. 5714-5725.
Guo et al., “3′-end-forming signals of yeast mRNA”, TIBS 21, 1996, pp. 477-481.
Guo et al., “Signals Sufficient for 3′-End Formation of Yeast mRNA”, Molecular and Cellular Biology, 1996, vol. 16, pp. 2772-2776.
Heidmann et al., “Flexibility and Interchangeability of Polyadenylation Signals inSaccharomyces cerevisiae”, Molecular and Cellular Biology, 1994, vol. 14, pp. 4633-4642.
Henikoff et al., “Transcription Terminates in Yeast Distal to a Control Sequence”, Cell, 1983, vol. 33, pp. 607-614.
Hofmann et al., “Sequence Determination of Human Papillomavirus Type 6a and Assembly of Virus-Like Particles inSaccharomyces cerevisiae”, Virology, 1995, vol. 209, pp. 506-518.
Jansen et al., “Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation”, Vaccine, 1995, vol. 13, pp. 1509-1514.
Kotula et al., “Evaluation of Foreign Gene Codon Optimization in Yeast: Expression of a Mouse IG Kappa Chain”, Bio/Technology, 1991, vol. 9, pp. 1386-1389.
Liu et al., “Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhanced prophylactic and therapeutic efficacy”, Vaccine, 2002, vol. 20, pp. 862-869.
McMurray et al., “Biology of human papillomaviruses”, International Journal of Experimental Pathology, 2001, vol. 82, pp. 15-33.
Neeper et al., “Expression of the major capsid protein of human papillomavirus type 11 inSaccharomyces cerevisae”, Gene, 1996, vol. 180, pp. 1-6.
Russo “Saccharomyces cerevisiaemRNA 3′ End Forming Signals are also Involved in Transcription Termination”, Yeast, 1995, vol. 11, pp. 447-453.
Schiffman et al., “Epidemiologic Evidence Showing That Human Papillomavirus Infection Causes Most Cervical Intraepithelial Neoplasia”, Journal of the National Cancer Institute, 1993, vol. 85, pp. 958-964.
Schiller et al., “Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report”, Journal of Clinical Virology, 2000, vol. 19, pp. 67-74.
Schiller et al., “Papillomavirus-Like Particle Vaccines”, Journal of the National Cancer Institute Monographs, 2000, No. 28, pp. 50-54.
Schiller et al., “Papillomavirus-Like Particles: Basic and Applied Studies”, UK: Leeds Medical Information, 1996, pp. 101-111.
Sharp et al., “Synonymous Codon Usage inSaccharomyces cerevisiae”, Yeast, 1991, vol. 7, pp. 657-678.
Suzich et al., “Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas”, Proc. Nat. Acad. Sci. USA, 1995, vol. 92, pp. 11553-11557.
Thalenfeld et al., “oli1 Transcripts in Wild Type and in a Cytoplasmic ‘Petite’ Mutant of Yeast”, The Journal of Biological Chemistry, 1983, vol. 258, pp. 14065-14068.
Tobery et al., “Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques”, Vaccine, 2003, vol. 21, pp. 1539-1547.
Zaret et al., “Mutationally Altered 3′ Ends of Yeast CYC1 mRNA Affect Transcript Stability and Translational Efficiency”, Journal of Molecular Biology, 1984, vol. 176, pp. 107-135.
Zaret et al., “DNA Sequence Required for Efficient Transcription Termination in Yeast”, Cell, 1982, vol. 28, pp. 563-573.
Zhou et al., “Papillomavirus Capsid Protein Expression Level Depends on the Match between Codon Usage and tRNA Availability”, Journal of Virology, 1999, vol. 73, pp. 4972-4982.
Database UniProt EBI, EMBL Accession No. Q05138, 1994.
GenBank Accession No. NC—001592, Jun. 29, 2005.
GenBank Accession No. M96297, Aug. 2, 1993.

Affiliated with

Also associated with

Rating

Optimized expression of HPV 52 L1 in yeast does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Optimized expression of HPV 52 L1 in yeast, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Optimized expression of HPV 52 L1 in yeast will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4173328